関連する実験動画

Updated: Feb 21, 2026

Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess

Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess

Published on: June 1, 2022

中鎖トリグリセリドによる断続的なケトジェニック・ファストは,COQ8Aに関連するコエンザイムQ10欠乏症におけるアタクシアを改善する:ケースレポート

Wiebke Hahn^1,2, Karla Erffmeier^1,2, Maximilian Schulze³

¹Department of Neurology, Philipps-University Marburg, Baldingerstraße, 35043 Marburg, Germany.

Molecular genetics and metabolism reports

|February 20, 2026

まとめ

ケトゲン性断続的な断食は,COQ8Aに関連するコエンザイムQ10欠乏症の患者でアタクシアを改善しました. このダイエット戦略は,ミトコンドリア・アタキシアの補助療法として有望であり,さらなる研究が必要である.

科学分野:

神経学神経学とは
メタボリック障害メタボリック障害
ミトコンドリア疾患

背景:

COQ8Aの変異は,プライマリコエンザイムQ10の欠乏を引き起こし,小脳アタクシアやなどの多様な神経学的症状を引き起こします.
コエンザイムQ10のサプリメント摂取は一般的であるが,補完的な戦略,特に非症の特徴に関する証拠は限られている.

研究の目的:

COQ8Aに関連したコエンザイムQ10欠乏症の患者における小脳無力症に対する補助療法としてケトゲン性断続性断食 (KIF) の有効性を調査する.

主な方法:

遺伝的にCOQ8A欠乏症とアタキシア/発作が確認された46歳の女性は,6ヶ月のKIFプロトコル (16:8中鎖トリグリセリドによる断続的な断食,その後断続的な断食のみ) を受けました.
臨床的アタクシアは,アタクシアの評価と評価のためのスケール (SARA) を使用して評価されました.
介入前と後に,拡散画像を含む脳MRIが実施されました.

主要な成果:

アタクシアの有意な改善が観察され,SARAスコアは8.5から6.0に低下しました.
ミオクロニック発作の減少は認められなかった.
脳のMRIは,小脳微細構造の整合性を改善する傾向を示した.

結論:

ケトゲン性断続的断食は,ミトコンドリア性無力症の有益な補助療法として役立つ可能性があります.
このダイエットアプローチは,COQ10欠乏症におけるアタクシアの改善の可能性を示しています.
これらの発見を検証するために,より大きな研究が必要である.

キーワード:

アタキシアアタクシアコエンザイムQ10欠乏症 IF-MCT研究について断続的な断食は断続的な断食です.ケトジェニックダイエットとはミトコンドリアの病気

さらに関連する動画

Inner Mitochondrial Membrane Sensitivity to Na+ Reveals Partially Segmented Functional CoQ Pools

Inner Mitochondrial Membrane Sensitivity to Na+ Reveals Partially Segmented Functional CoQ Pools

Published on: July 20, 2022

Assessment of the Metabolic Effects of Isocaloric 2:1 Intermittent Fasting in Mice

Assessment of the Metabolic Effects of Isocaloric 2:1 Intermittent Fasting in Mice

Published on: November 27, 2019

関連する概念動画

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...

Chronic Pancreatitis II: Collaborative Care

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:

Metabolic States of the Body: Fasting and Starvation

Metabolic States of the Body: Fasting and Starvation

During the initial hours of fasting, the body uses up its glycogen stores as an energy source. Once these glycogen reserves are depleted, the body begins breaking down stored triglycerides and structural proteins. During this stage, glycerol becomes a key substrate for gluconeogenesis, while free fatty acids undergo beta-oxidation to provide energy for tissues, such as skeletal muscle. In the fasting state, the body spares protein breakdown as much as possible to conserve muscle and structural...

Animal Mitochondrial Genetics

Animal Mitochondrial Genetics

Among all the organelles in an animal cell, only mitochondria have their own independent genomes. Animal mitochondrial DNA is a double-stranded, closed-circular molecule with around 20,000 base pairs. Mitochondrial DNA is unique in that one of its two strands, the heavy, or H, -strand is guanine rich, whereas the complementary strand is cytosine rich and called the light, or L, -strand. Compared to nuclear DNA, mitochondrial DNA has a very low percentage of non-coding regions and is marked by...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...